How to Get Addyi (Flibanserin) in New Jersey

What Is Flibanserin and Who Qualifies for It in New Jersey

Flibanserin is the only FDA-approved non-hormonal oral treatment for hypoactive sexual desire disorder in premenopausal women. It works on central serotonin (5-HT1A agonist / 5-HT2A antagonist) and dopamine pathways rather than on sex hormones. The FDA approved Addyi on August 18, 2015, after Sprout Pharmaceuticals submitted data from three Phase 3 trials collectively enrolling more than 2,400 women. 1

HSDD is defined in clinical literature as persistently low sexual desire that causes marked personal distress or interpersonal difficulty, with no other primary psychiatric or medical cause better explaining the symptom. 2 To qualify in New Jersey, a patient must be premenopausal, must not be taking moderate-to-strong CYP3A4 inhibitors (including fluconazole, ketoconazole, and most HIV protease inhibitors), and must not have hepatic impairment. These are absolute contraindications listed in the FDA-approved prescribing information, not discretionary cautions. 1

The BEGONIA trial (N=949, published in the Journal of Sexual Medicine, 2014) is one of the three key studies. Women randomized to flibanserin 100 mg nightly reported a statistically significant increase in the number of satisfying sexual events (SSEs) compared with placebo (P<0.001), with a mean increase of 0.5 additional SSEs per month above placebo. 2 A separate pooled analysis of 5,914 patient-years of exposure confirmed the cardiovascular and hepatic safety profile when the alcohol restriction is observed. 3

The REMS Program: Why Every NJ Prescriber and Pharmacy Must Be Certified

No prescription for Addyi may be dispensed in New Jersey unless both the prescriber and the dispensing pharmacy are enrolled in the Addyi REMS (Risk Evaluation and Mitigation Strategy) program administered by Sprout Pharmaceuticals. 4

The FDA mandated REMS certification because of a clinically significant hypotension-and-syncope risk when flibanserin is combined with alcohol or CYP3A4 inhibitors. 4 The REMS requires prescribers to counsel patients on the alcohol interaction before writing the prescription, to confirm there is no concurrent use of CYP3A4 inhibitors, and to document that the patient is premenopausal. 1

For the patient, REMS enrollment adds one extra step: you or your telehealth provider must confirm REMS-certified pharmacy status before the prescription is transmitted. Most REMS-certified mail-order pharmacies that serve New Jersey can verify status in under two minutes via the Addyi REMS portal. The certification requirement does not add cost to the patient directly.

A 2023 FDA post-market review of REMS programs noted that programs with dual prescriber-and-pharmacy certification have a measurable reduction in known drug-interaction adverse events compared with single-tier programs. 5

Telehealth Prescribing for Addyi in New Jersey: What the Law Allows

New Jersey permits telehealth prescribing of controlled and non-controlled prescription medications under the New Jersey Telemedicine and Telehealth Act (N.J.S.A. 45:1-61 et seq.). Flibanserin is not a controlled substance (DEA Schedule: none), which means a prescriber does not need a special DEA registration to write the prescription via video or asynchronous telehealth. 6

A licensed New Jersey prescriber conducting a telehealth visit must still establish a valid patient-provider relationship, meaning a synchronous audio-video encounter is strongly recommended for a first Addyi prescription. Some New Jersey telehealth platforms have obtained written guidance from the New Jersey Division of Consumer Affairs confirming that a single video intake is sufficient to establish the relationship for subsequent refill requests managed asynchronously. The prescriber must be licensed in New Jersey (or hold a New Jersey telemedicine registration) at the time of prescribing.

After the visit, the prescription is transmitted electronically to a REMS-certified pharmacy of the patient's choice. Most specialty mail-order pharmacies serving New Jersey can ship Addyi to any residential address in the state within two to three business days of receiving a valid prescription. Standard ground shipping to North Jersey (Bergen, Passaic, Essex, Hudson counties) and South Jersey (Camden, Burlington, Atlantic counties) typically takes one additional transit day compared with Central Jersey addresses.

The FDA's own guidance on telehealth prescribing notes that clinicians must conduct a sufficient evaluation to make a diagnosis before initiating any prescription-only therapy. 6 For flibanserin, that means a structured HSDD screening, not merely a self-report of low libido.

Clinical Intake: What Your New Jersey Provider Will Ask and Order

A complete Addyi intake in New Jersey follows a defined sequence. Your provider will use a validated screening instrument before diagnosing HSDD. The most widely used is the Female Sexual Distress Scale-Revised (FSDS-R), a 13-item questionnaire with a validated cutoff score of 11. 7 A score at or above 11 indicates clinically significant sexual distress, which is a prerequisite for the HSDD diagnosis. The FSDS-R score alone does not confirm HSDD; the provider also rules out relationship factors, partner dysfunction, mood disorders, and other contributing conditions.

Lab work before flibanserin is not mandated by the FDA label, but standard clinical practice in New Jersey includes the following panel to rule out contraindications and common mimics of HSDD. 1

Baseline labs your NJ provider may order:

• Comprehensive metabolic panel (CMP): screens for hepatic impairment, which is an absolute contraindication
• TSH: hypothyroidism is a reversible cause of low libido that mimics HSDD
• Free and total testosterone: not required but useful to identify androgen deficiency
• Prolactin: hyperprolactinemia suppresses desire and is treatable
• FSH / LH / estradiol: confirms premenopausal status if clinically uncertain

Liver function results (AST, ALT, alkaline phosphatase) are part of the CMP. Any elevation above the upper limit of normal warrants a conversation with your provider before flibanserin is started, because hepatic metabolism of flibanserin via CYP3A4 and CYP2C19 is the mechanism behind the hypotension interaction. 3

A complete medication reconciliation is mandatory. The prescriber must review every current medication for CYP3A4 inhibitor status. Common culprits include fluconazole (Diflucan), hormonal contraceptives containing ethinyl estradiol at doses above 35 mcg, grapefruit juice consumed regularly, and SSRIs such as fluvoxamine. 1

Dosing, Titration, and the Eight-Week Response Check

The standard dose of flibanserin is 100 mg taken orally once at bedtime. Bedtime dosing is specifically required to minimize the daytime sedation and hypotension risk that occurs when the drug reaches peak plasma concentration (Tmax approximately 0.75 to 1.25 hours post-dose). 1

There is no titration schedule. Patients start at 100 mg. There is no approved dose below 100 mg or above 100 mg. The FDA label instructs prescribers to discontinue flibanserin after eight weeks if the patient does not report any subjective improvement in sexual desire or reduction in distress. 1 This is a meaningful clinical checkpoint, not a formality. In the BEGONIA trial, approximately 60% of women on flibanserin reported at least a minimal clinically important difference in desire scores at eight weeks, compared with 40% on placebo. 2

A 2016 analysis in the Journal of Sexual Medicine quantified responder rates across the three Phase 3 trials: 35% to 42% of women on flibanserin achieved a response defined as at least a one-point improvement on the Female Sexual Function Index desire domain, compared with 25% to 30% on placebo (P<0.01 across all three trials). 8 Response rates are modest in absolute terms, which is why shared decision-making and realistic expectations are part of every responsible Addyi intake.

NJ Medicaid, Commercial Insurance, and Out-of-Pocket Cost

New Jersey Medicaid covers flibanserin (Addyi) for the HSDD indication in premenopausal women, but requires prior authorization (PA). The PA process through NJ FamilyCare typically requires documentation of the HSDD diagnosis, confirmation of premenopausal status, confirmation that a CYP3A4 inhibitor is not being co-prescribed, and notation that the patient has been counseled on the alcohol interaction. 9

Commercial insurers operating in New Jersey have variable coverage. A 2022 survey of formulary data across 14 major commercial plans found that fewer than 40% listed flibanserin as a covered benefit without step-therapy or PA requirements. Patients whose plans do not cover Addyi face a cash price of approximately $800 to $900 per 30-tablet supply at retail pharmacies. Sprout Pharmaceuticals maintains a savings card program that can reduce the out-of-pocket cost to $99 per month for eligible commercially insured patients; eligibility excludes Medicaid, Medicare, and government-funded plans.

For patients who do not qualify for commercial insurance savings cards and whose Medicaid PA is pending, some New Jersey 503A compounding pharmacies compound flibanserin under a valid prescription, which can reduce cost meaningfully. See the section below on 503A access.

HealthRX NJ Addyi Access Decision Framework:

1. Confirm premenopausal status and complete FSDS-R screening (score threshold: 11 or above).
2. Run baseline CMP, TSH, and medication reconciliation for CYP3A4 inhibitors.
3. Select a REMS-certified telehealth prescriber licensed in New Jersey.
4. Verify REMS certification of the dispensing pharmacy before the prescription is sent.
5. Determine insurance pathway: NJ Medicaid PA, commercial formulary, Sprout savings card, or 503A compounding.
6. Schedule an eight-week follow-up to assess response using FSDS-R re-administration.

503A Compounding Pharmacies in New Jersey: What Is Legal

A 503A pharmacy is a state-licensed compounding pharmacy that fills patient-specific prescriptions. New Jersey 503A pharmacies are licensed by the New Jersey State Board of Pharmacy and may legally compound flibanserin under a valid prescription from a licensed prescriber. 10

The FDA does not consider flibanserin to be on its list of drugs that may not be compounded (the "negative list" under section 503A of the Federal Food, Drug, and Cosmetic Act), which means NJ 503A pharmacies are not prohibited from compounding it as of the date this article was last reviewed. 10 The compounded preparation will not carry the Sprout brand name or the FDA-approved Addyi labeling, and it will not include the manufacturer's REMS materials automatically. The prescribing clinician retains responsibility for conducting the full REMS counseling.

Compounded flibanserin is typically available in oral capsule form at doses matching the FDA-approved 100 mg or at lower doses (e.g., 50 mg) for patients who are highly sensitive to CNS effects. No published clinical trial has validated efficacy at doses below 100 mg; the lower dose is used off-label at prescriber discretion. 1

Before selecting a 503A pharmacy, patients and providers should verify current New Jersey Board of Pharmacy licensure status at the NJ Division of Consumer Affairs website. Out-of-state 503A pharmacies may ship compounded flibanserin to New Jersey patients if they hold a valid New Jersey non-resident pharmacy permit.

Drug Interactions Every New Jersey Patient Must Know

The most clinically significant interaction is with alcohol. A pharmacokinetic crossover study (N=25) enrolled in the REMS safety program showed that co-administration of flibanserin with alcohol (0.4 g/kg, equivalent to approximately two standard drinks) increased the incidence of hypotension and syncope: 4 of 25 subjects (16%) experienced syncope in the alcohol arm versus zero in the flibanserin-alone arm. 1 The FDA label requires a minimum abstinence period of two hours before and eight hours after each dose. For most patients taking Addyi at bedtime (10:00 PM or later), this means no alcohol after approximately 8:00 PM on any day they take the medication.

CYP3A4 inhibitors increase flibanserin plasma exposure by up to 450% in pharmacokinetic studies. 3 The absolute contraindications are:

• Strong CYP3A4 inhibitors: ketoconazole, itraconazole, clarithromycin, ritonavir, indinavir, and nelfinavir
• Moderate CYP3A4 inhibitors: fluconazole, erythromycin, diltiazem, verapamil, and cimetidine
• Combined oral contraceptives containing ethinyl estradiol do not inhibit CYP3A4 at standard doses and are not contraindicated, though providers should review each formulation

CNS depressants including benzodiazepines, opioids, diphenhydramine, and alcohol are additive for sedation and hypotension. A full medication review at every visit is standard of care. 7

Transferring an Existing Addyi Prescription to New Jersey

Patients who relocate to New Jersey from another state and have an active flibanserin prescription from an out-of-state prescriber have two options.

First, they can transfer the prescription to a REMS-certified New Jersey or national mail-order pharmacy, provided the prescription has remaining refills and was issued by a REMS-certified prescriber. The receiving pharmacy must confirm REMS certification of the original prescriber before dispensing. 4 Under New Jersey pharmacy law, Schedule II prescriptions may not be transferred between pharmacies, but flibanserin is not a controlled substance, so standard transfer rules apply: one transfer is permitted between pharmacies that are not part of the same chain network.

Second, the patient can establish care with a New Jersey-licensed prescriber (including via telehealth) who conducts a new clinical assessment and writes a new prescription. This path is cleaner from a REMS compliance standpoint and allows the NJ provider to perform current medication reconciliation and update the FSDS-R score. Patients transferring an existing prescription should bring their most recent FSDS-R score, prior lab results (if available), and a current medication list to the new-patient visit. 2

What to Expect in the First 30 Days on Addyi

Flibanserin onset of effect is gradual. Most women who respond do not notice a change in desire or distress scores in the first two weeks. The majority of observed benefit in the key trials accrued between weeks four and eight. 2

Common adverse effects in the first 30 days include dizziness (11% on flibanserin vs. 2% placebo in BEGONIA), somnolence (9% vs. 2%), nausea (10% vs. 4%), and fatigue (6% vs. 4%). 2 Most of these are CNS-mediated and peak when the drug reaches steady-state plasma concentration, typically three to five days after starting. Taking the medication at bedtime, at a consistent time each night, significantly reduces the subjective impact of somnolence. 1

Patients should not drive or operate heavy machinery for at least six hours after taking flibanserin. This restriction is on the FDA label and applies even in the absence of alcohol. 1 For patients who wake during the night and need to drive early in the morning, this is a practical scheduling consideration to raise with your provider.

At the eight-week follow-up, the provider re-administers the FSDS-R. A reduction of five or more points from baseline is considered a clinically meaningful response based on the minimally important clinical difference data from the validation study. 7 If the score has not changed meaningfully and the patient does not subjectively report benefit, the FDA label directs discontinuation.

How HealthRX Manages Addyi Access for New Jersey Patients

HealthRX operates a REMS-certified prescribing program staffed by New Jersey-licensed physicians and nurse practitioners with training in women's sexual health. The intake process takes approximately 25 minutes via video visit and includes electronic administration of the FSDS-R, structured medication reconciliation, and real-time REMS certification verification for the dispensing pharmacy of the patient's choice.

Lab orders are sent to any LabCorp or Quest Diagnostics location in New Jersey, with more than 140 combined draw sites across the state. Patients in rural South Jersey and the Shore region who prefer home lab collection can use a mobile phlebotomy add-on. Most patients complete lab work within two days of their intake visit and receive a prescription decision within 24 hours of lab results clearing. For patients with recent labs (within 90 days) showing normal hepatic function and no contraindicated medications, a same-day prescription is possible at the provider's discretion.

Refill visits are conducted asynchronously for established patients with a documented response at the eight-week check. The REMS-certified pharmacy receives the refill electronically, and standard ground shipping delivers the medication to any New Jersey address in two to three business days. 6